A randomized study of interferon-alpha versus interferon-alpha and low-dose arabinosyl cytosine in chronic myeloid leukemia.

Commentary (Goldman)—Chronic Myeloid Leukemia: Changing the Treatment Paradigms

Serum-tryptase at diagnosis: a novel biomarker improving prognostication in Ph(+) CML.

Automated Synthesis and Visualization of a Chemotherapy Treatment Regimen Network

Combination of pegylated IFN-α2b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia.

Monitoring twenty-six chronic myeloid leukemia patients by BCR-ABL mRNA level in bone marrow:a single hospital experience.

Preclinical studies on targeted delivery of multiple IFNα2b to HLA-DR in diverse hematologic cancers.

CLINICAL TRIALS AND OBSERVATIONS Results of high-dose imatinib mesylate in intermediate Sokal risk chronic myeloid leukemia patients in early chronic phase: a phase 2 trial of the GIMEMA CML Working Party

Results of high-dose imatinib mesylate in intermediate Sokal risk chronic myeloid leukemia patients in early chronic phase: a phase 2 trial of the GIMEMA CML Working Party.

Signalling pathways in prostate carcinogenesis: potentials for molecular-targeted therapy.

proteasome Inhibition: Thinking Outside the Box

A randomized study of interferon-alpha versus interferon-alpha and low-dose arabinosyl cytosine in chronic myeloid leukemia.

Commentary (Goldman)—Chronic Myeloid Leukemia: Changing the Treatment Paradigms

Serum-tryptase at diagnosis: a novel biomarker improving prognostication in Ph(+) CML.

Automated Synthesis and Visualization of a Chemotherapy Treatment Regimen Network

Combination of pegylated IFN-α2b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia.

Monitoring twenty-six chronic myeloid leukemia patients by BCR-ABL mRNA level in bone marrow:a single hospital experience.

Preclinical studies on targeted delivery of multiple IFNα2b to HLA-DR in diverse hematologic cancers.

CLINICAL TRIALS AND OBSERVATIONS Results of high-dose imatinib mesylate in intermediate Sokal risk chronic myeloid leukemia patients in early chronic phase: a phase 2 trial of the GIMEMA CML Working Party

Results of high-dose imatinib mesylate in intermediate Sokal risk chronic myeloid leukemia patients in early chronic phase: a phase 2 trial of the GIMEMA CML Working Party.

Signalling pathways in prostate carcinogenesis: potentials for molecular-targeted therapy.

proteasome Inhibition: Thinking Outside the Box

A randomized study of interferon-alpha versus interferon-alpha and low-dose arabinosyl cytosine in chronic myeloid leukemia.

Commentary (Goldman)—Chronic Myeloid Leukemia: Changing the Treatment Paradigms

Serum-tryptase at diagnosis: a novel biomarker improving prognostication in Ph(+) CML.

Automated Synthesis and Visualization of a Chemotherapy Treatment Regimen Network

Combination of pegylated IFN-α2b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia.

Monitoring twenty-six chronic myeloid leukemia patients by BCR-ABL mRNA level in bone marrow:a single hospital experience.

Preclinical studies on targeted delivery of multiple IFNα2b to HLA-DR in diverse hematologic cancers.

CLINICAL TRIALS AND OBSERVATIONS Results of high-dose imatinib mesylate in intermediate Sokal risk chronic myeloid leukemia patients in early chronic phase: a phase 2 trial of the GIMEMA CML Working Party

Results of high-dose imatinib mesylate in intermediate Sokal risk chronic myeloid leukemia patients in early chronic phase: a phase 2 trial of the GIMEMA CML Working Party.

Signalling pathways in prostate carcinogenesis: potentials for molecular-targeted therapy.

proteasome Inhibition: Thinking Outside the Box